Altria Stock’s 27% YTD Rally: Does the Math Still Support More Upside in 2026?

Key Takeaways for Altria Group Stock as of July 2026

• Eleven sell-side analysts carry a $70 mean target on Altria stock, sitting 3% below today’s $73, while the wider 13-analyst panel splits four buys, seven holds, one underperform and one sell.
• TIKR’s mid-case model puts Altria stock at $86 by December 2030, a 19% total return worth 4% annualized from here.
• With normalized EPS climbing 7.3% in the first quarter alone, Altria stock still trades rich against a Street target that hasn’t caught up.
• May’s FDA vape enforcement shift threatens the very cross-category migration fueling that growth.

Altria stock trades above the Street’s own price target while a new FDA rule threatens the volume shift behind its EPS growth. See the full model on TIKR for free →

Altria Stock’s Q1 EPS Beat Hides a Bigger Fight Over Vapes

Altria Group (MO) grew adjusted diluted EPS 7.3% in the first quarter of 2026, a number CEO Billy Gifford put on the record in what turned out to be his final earnings call before stepping down.

That growth ran through smokeable products, where segment adjusted operating income climbed 6.3% behind 6.3% net price realization, and Marlboro expanded its premium segment share to 59.5%.

Beneath that headline, the real driver was a shift management flagged as fragile rather than permanent. On the Q1 earnings call, Gifford tied the quarter’s strength directly to a change in consumer behavior: “We delivered a strong start to the year, growing adjusted diluted EPS by 7.3% in the first quarter.” That growth, he explained, came as the moderation in cross-category movement between illicit e-vapor and cigarettes pushed smokers back toward Marlboro, Basic and Altria’s own nicotine pouches.

That same shift extends to on!, where reported shipment volume grew nearly 18% to over 46 million cans as Helix rolled on! PLUS out nationwide, now sitting in roughly 100,000 stores. Altria reaffirmed full-year adjusted diluted EPS guidance of $5.56 to $5.72, a 2.5% to 5.5% increase over 2025’s $5.42 base.

The tension sits outside Altria’s own numbers. In May, the FDA introduced an “enforcement discretion” policy letting some vape and pouch makers sell without the license the agency has required for years, a shift that could immediately qualify 100 to 200 products from a pool of roughly 1,000 pending applications. Gifford himself called the e-vapor category “still upside down,” with about 70% of volume still illicit disposables. If loosened enforcement reopens the door those illicit products once filled, the cross-category migration that just lifted Altria’s smokeable and oral tobacco results could run in reverse.

Altria’s on! shipments jumped 18% while the FDA loosens vape rules that once kept rivals boxed out. Track Altria stock’s full segment breakdown on TIKR for free →

Wall Street Holds Steady on Altria Stock Even as Shares Outrun the Mean Target

The Street rates Altria stock a consensus hold, with the 13-analyst panel split four buys, seven holds, one underperform and one sell.

Accordingly, eleven of those analysts carry a mean target of $70, a level Altria stock has already cleared to trade near $73, leaving the average call roughly 3% below the market’s own price.

The high end of that range still reaches $82, but the gap between the $71 median target and the current quote shows a Street that hasn’t moved as fast as the shares.

Wall Street Expects Altria Stock’s Normalized EPS to Keep Climbing Toward $5.56 to $5.72 in 2026

Altria’s normalized EPS grew 7.3% year over year in the quarter ended March 31, 2026, hitting $1.32 and confirming the pace management had already guided toward for the full year.

Analysts expect normalized EPS of $1.49 in the June quarter and $1.50 in September, before easing to $1.38 to close out the year, a path that lands inside management’s reaffirmed $5.56 to $5.72 guidance range.

Analysts consensus calls for $1.36 in the March 2027 quarter before normalized EPS rises to $1.55 by June 2027, keeping annual growth in the mid-single digits rather than accelerating.

That trajectory leans on on! holding its volume gains against a vape market the FDA just made easier to enter. The FDA’s pending 180-day decision on six new on! PLUS flavor applications will show whether the pouch business can keep delivering the growth these normalized EPS estimates already assume.

Altria Stock’s Normalized EPS Trails Philip Morris But Outpaces Turning Point Brands

Altria’s normalized EPS of $1.32 in the quarter ended March 31, 2026 sits well below Philip Morris International’s (PMI) $1.83 over the same period, while Turning Point Brands (TPB) posted $0.73. That gap holds through the forward estimates too, with Altria projected at $1.49 for the June quarter against $2.06 for Philip Morris and just $0.30 for Turning Point Brands.

Philip Morris carries the larger absolute earnings base and the steeper near-term estimate, while Turning Point Brands shows a sharp forward EPS dip before climbing back to $0.84 by June 2027. Altria’s trajectory sits between the two: less growth than Philip Morris, but a steadier base than Turning Point Brands’ swing.

The competitive read is that Altria’s normalized EPS growth looks modest next to Philip Morris, leaving less room for the stock to re-rate on earnings power alone if on!’s volume gains stall.

TIKR’s $86 Target on Altria Stock Holds if On! Outgrows the FDA’s Vape Reset

TIKR’s mid-case model values Altria stock at $86 by December 2030, implying a 19% total return from the current price of $73, or 4% annualized over the next 4.5 years.

That annualized return sits below what equity investors typically demand from a stock trading above the Street’s own mean target which positions Altria stock more as a steady compounder than a re-rating story.

TIKR sees Altria stock reaching $86 by 2030, a 19% total return worth 4% annualized. Run your own scenario on TIKR for free →

Should You Invest in Altria Group, Inc.?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up Altria Group, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track Altria Group, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Access Professional Tools to Analyze MO stock on TIKR for Free →